Results 231 to 240 of about 6,578,993 (340)

Smoldering multiple myeloma in the United States: a population-based analysis. [PDF]

Blood Adv
Wang SY, Wang R, Schoen M, Huber JH, Feuer EJ, Ruhl J, Neparidze N, Ma X, Davidoff AJ, Chang SH.   +9 more
europepmc   +1 more source

Predictive value of MRD monitoring by BCR clonality in the ZUMA‐7 randomized clinical trial for CAR T therapy in r/r lymphoma

British Journal of Haematology, EarlyView.
Brodie Miles, Daqin Mao, Saran Vardhanabhuti, Davide Bedognetti, Simone Filosto, Rhine Shen   +5 more
wiley   +1 more source

Biochemical bone biomarkers in plasma cell dyscrasias

British Journal of Haematology, EarlyView.
Visual abstract depicting that bone turnover markers reflect dynamic alterations in bone remodelling across the spectrum of plasma cell dyscrasias but remain limited by assay variability, biological confounding and incomplete integration with imaging and risk stratification.
Guido Nador, Rohit Vijjhalwar, Muhammad Kassim Javaid, Claire M. Edwards, Karthik Ramasamy   +4 more
wiley   +1 more source

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

Haematologica, 2014
Neha Korde, Mattias Carlsten, Min-Jung Lee, Alex Minter, Esther Tan, Mary Kwok, Elisabet Manasanch, Manisha Bhutani, Nishant Tageja, Mark Roschewski, Adriana Zingone, Rene Costello, Marcia Mulquin, Diamond Zuchlinski, Irina Maric, Katherine R. Calvo, Raul Braylan, Prashant Tembhare, Constance Yuan, Maryalice Stetler-Stevenson, Jane Trepel, Richard Childs, Ola Landgren   +22 more
doaj   +1 more source

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trial

British Journal of Haematology, EarlyView.
A subgroup analysis of efficacy, safety and QOL in patients who received selinexor in combination with bortezomib and dexamethasone (SVd) with and without selinexor dose reduction and who had lenalidomide‐refractory disease in the phase 3 BOSTON trial showed improvements in efficacy, quality of life (QOL) and safety outcomes with selinexor dose ...
Sosana Delimpasi, Ivan Špička, Jason P. Butler, Don A. Stevens, Mercedes Gironella Mesa, Ceri Bygrave, Giovanni Marino Merlo, Charles la Porte, Meletios A. Dimopoulos   +8 more
wiley   +1 more source

Real-world evidence of measurable residual disease assessment in multiple myeloma. [PDF]

Blood Adv
Cedena MT, Puig N, Paiva B, de la Puerta JE, Pérez-Montaña A, Casanova M, Breña J, García A, de Arriba F, Martínez-Chamorro C, Sirvent M, Blanchard MJ, Alonso R, Álvarez MÁ, Capote FJ, García-Sánchez R, Pérez JJ, Rodriguez-Otero P, Lahuerta JJ, Martínez-López J, Martínez-López J, Mateos MV, San-Miguel J.   +22 more
europepmc   +1 more source

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

British Journal of Haematology, EarlyView.
Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less ...
Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima   +9 more
wiley   +1 more source

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: A prospective analysis in three large cohorts [PDF]

, 2018
Birmann, Brenda M, Buring, Julie E, Colditz, Graham A, Giovannucci, Edward, Lee, I-Min, Marinac, Catherine R, Rebbeck, Timothy R, Rosner, Bernard A, Townsend, Mary K   +8 more
core   +1 more source

A Rare Case Report of Immunoglobulin D Subtype Multiple Myeloma Complicated With Hyperlipidemia. [PDF]

Case Rep Hematol
Yang L, Zhou Z, Qu X, Jing L, Liu J, Chen L, Ma L.   +6 more
europepmc   +1 more source

Prospective implementation of the HCT frailty scale in adults with lymphoproliferative syndromes candidates for autologous haematopoietic stem cell transplantation: Results from a multicentre GETH‐TC study

British Journal of Haematology, EarlyView.
Summary This prospective study evaluated the incidence and dynamics of frailty in 156 adults with lymphoproliferative syndromes undergoing autologous haematopoietic stem cell transplantation (HSCT). Frailty was assessed using the haematopoietic cell transplantation (HCT) frailty scale in patients from 15 Spanish institutions at initial consultation ...
Javier Cornago, Mónica Baile, Marina Acera, Laura Fox, María del Mar Pérez‐Artigas, Ana Santamaría, María del Carmen Quintela, Andrés Sánchez‐Salinas, Joaquina M. Salmerón, Verónica Illana, Zahra Abdallahi‐Lefdil, Laura Pardo, Laura Solán, José Luis López‐Lorenzo, Sara Fernández‐Luis, Leddy Patricia Vega, Sara Villar, Patricia Beorlegui‐Murillo, Mónica Molina, Albert Esquirol, Isabel Izquierdo, Julia Ribes, Alberto Mussetti, Esperanza Lavilla, Olga Alda, Javier López‐Marín, Leyre Bento, Silvia Filaferro, Pascual Balsalobre, Anna Sureda, María Queralt Salas   +30 more
wiley   +1 more source